Gilead signs generic licensing deals for experimental Ebola drug
A late-stage trial is testing the drug in people at high risk after exposure. The deals are intended to line up manufacturing and supply before trial results and regulatory filings
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].

